Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Single-Treatment Study to Assess the Safety and Tolerability of Lyophilized Lucinactant in Adults With COVID-19 Associated Acute Lung Injury

NCT04389671 is registered in ClinicalTrials.gov with Windtree Therapeutics as lead sponsor.

NCT NCT04389671
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04389671 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Single-Treatment Study to Assess the Safety and Tolerability of Lyophilized Lucinactant in Adults With COVID-19 Associated Acute Lung Injury
Lead sponsor
Windtree Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
January 5, 2021
Completion date
February 20, 2022
Enrollment
20 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

acute lung injury/acute respiratory distress syndrome (ards), covid-19